Thrombolytic therapy: A review of its use in acute myocardial infarction

Annals of Pharmacotherapy

Volumn 32, Issue 7-8, 1998, Pages 769-784

  Bizjak, Eric D ^a,b   Mauro, Vincent F ^a,c  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Acute myocardial infarction; Thrombolytic agents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; HIRUDIN; RETEPLASE; SARUPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG HYPERSENSITIVITY; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; META ANALYSIS; MORTALITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031826125     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17350     Document Type: Review

References (116)

1. American Heart Association. 1997 heart and stroke statistical update. Coronary heart disease. Available at: http://www.amhrt.org/Scientific/ 1997/stats/CorHtDis.html. Accessed December 1, 1997.
2. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
3. Raitt MH, Maynard C, Wagner GS, Cerqueira MD, Selvester RH, Weaver WD. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Circulation 1996;93:48-53.
4. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, Van den Brand M, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986;7:729-42.
5. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317:850-5.
6. Sheehan FH, Doerr R, Schmidt WG, Bolson EL, Uebis R, Von Essen R, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988;12:289-300.
7. Kennedy JW, Ritchie JL, Davis KB, Fritz JK. Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983;309:1477-82.
8. Meinertz T, Kasper W, Schumacher M, Just H, for the APSAC Multicenter Trial Group. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol 1988;62:347-51.
9. Van de Werf F, Arnold AER, for the European Cooperative Study Group for recombinant tissue plasminogen activator Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 1988;297:1374-9.
10. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J 1985;6:556-85.
11. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med 1992;326:242-50.
12. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (part II). N Engl J Med 1992;326:310-8.
13. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 1996;14:17-29.
14. Gaffney PJ. Thrombosis: a molecular approach to therapy. Nature 1981; 290:445-6.
15. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski memorial lecture. Thromb Haemost 1980;43:77-89.
16. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991;78:3114-24.
17. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978;272:549-50.
18. Tillett WS, Gamer RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933;58:485-502.
19. Sherry S. The fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest 1954;35:1054-63.
20. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958;71: 287-96.
21. Product information. Streptase (streptokinase). Westborough, MA: Astra Pharmaceutical Products, March 1991.
22. Goa KL, Henwood JM, Stolz JF, Langley MS, Clissold SP. Intravenous streptokinase: a reappraisal of its therapeutic use in acute myocardial infarction. Drugs 1990;39:693-719.
23. Product information. Eminase (anistreplase). Pittsburgh, PA: SmithKline Beecham, 1996.
24. Marinac JS, North DS, Stringer KA. Anistreplase: a novel thrombolytic agent for acute myocardial infarction. DICP Ann Pharmacother 1990;24: 607-15.
25. Product information. Activase (alteplase). South San Francisco, CA: Genentech, June 1996.
26. Zeller FP, Spinler SA. Alteplase: a tissue plasminogen activator for acute myocardial infarction. Drug Intell Clin Pharm 1988;22:6-14.
27. Product information. Retavase (reteplase). Gaithersburg, MD: Boehringer Mannheim Corporation, October 1996.
28. Noble S, McTavish D. Reteplase: a review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 1996;52:589-605.
29. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
30. McClintock DK, Bell PH. The mechanism of activation of human plasminogen by streptokinase. Biochem Biophys Res Commun 1971;43: 694-702.
31. Verstraete M, Collen D. Pharmacology of thrombolytic drugs. J Am Coll Cardiol 1986;8(suppl):33B-40B.
32. Fletcher AP, Alkjaersig N, Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J Clin Invest 1958;37:1306-15.
33. Chesser SL, Mauro VF. Antistreptokinase antibodies following a dose of streptokinase. Ann Pharmacother 1994;28:204-6.
34. Elliott JM, Cross DB, Cederholm-Williams SA, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol 1993;71:640-5.
35. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 1981;290:505-8.
36. Monassier JP, Hanssen M. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II study. Drugs 1987;33(suppl 3):247-52.
37. Gillis JC, Wagstaff AJ, Goa KL. Alteplase: a reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 1995;50:102-36.
38. Product information. Activase (alteplase). South San Francisco, CA: Genentech, November 1987.
39. Neuhaus K-L, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566-9.
40. Neuhaus K-L, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992;19:885-91.
41. Martin U, Bader R, Bohm E, Kohnert U, von Mollendorf E, Fischer S, et al. Boehringer Mannheim 06.022: a novel recombinant plasminogen activator. Cardiovasc Drug Rev 1993;11:299-311.
42. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;97:211-8.
43. Simon TL, Ware JH, Stengle JM. Clinical trials of thrombolytic agents in myocardial infarction. Ann Intern Med 1973;79:712-9.
44. European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med 1979;301:797-802.
45. The ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous Streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465-71.
46. GISSI (Gruppo Italiano per lo studio della Streptochinasi nell'Infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
47. GISSI (Gruppo Italiano per lo studio della Streptochinasi nell'Infarto Miocardico). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987;2:871-4.
48. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous Streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988;2:349-60.
49. AIMS (APSAC Intervention Mortality Study) Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;1: 545-9.
50. AIMS (APSAC Intervention Mortality Study) Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 1990;335:427-31.
51. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet 1988;2:525-30.
52. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR, for the ASSET (Anglo-Scandinavian Study of Early Thrombolysis) Study Group. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Lancet 1990;335:1175-8.
53. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342: 767-72.
54. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
55. Drug topics red book 1996. Montvale, NJ: Medical Economics, 1996.
56. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-5.
57. ISIS-3 (Third International Study of Infarct Survival Collaborative Group). ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
58. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
59. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995;346:329-36.
60. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
61. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
62. GISSI-2 and International Study Group. Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Eur Heart J 1992;13:1692-7.
63. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-7.
64. De Bono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-8.
65. Califf RM, White HD, Van de Werf F, Sadowski Z, Armstong PW, Vahanian A, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. Circulation 1996;94:1233-8.
66. Topol EJ, Califf RM, Lee KL. More on the GUSTO trial (letter). N Engl J Med 1994;331:277-8.
67. Friedman HS. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized (letter). N Engl J Med 1994;330:504.
68. Chelluri L, Sirio CA, Angus DC. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized (letter). N Engl J Med 1994;330: 505.
69. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
70. Goldman L, Garber AM, Grover SA, Hlatky MA. Task force 6: effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27:1020-30.
71. Armentano R, Favaloro RG. Is the use of t-PA as compared with streptokinase cost effective (letter)? N Engl J Med 1995;333:1009-10.
72. Stringer KA, Lopez LM. Acute myocardial infarction. In: DiPiro JT, Talbert RL, Yee GC, Matzke JR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 3rd ed. Stamford, CT: Appleton & Lange, 1997:295-322.
73. Eisenberg C. Validity of the GUSTO trial's main conclusion. Pharmacotherapy 1997;17:850-2.
74. Ware JH, Antman EM. Equivalence trials. N Engl J Med 1997;337: 1159-61.
75. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-54.
76. Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996;78: 1-8.
77. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-94.
78. The GUSTO Angiographie Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
79. Stringer KA, Lindenfeld J. The GUSTO trial: is the open-artery hypothesis proven? Ann Pharmacother 1994;28:97-8.
80. Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch JM, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891-8.
81. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336:847-60.
82. Markwardt F. Past, present, and future of hirudin. Haemostasis 1991;21: 11-26.
83. Antman EM, for the TIMI-9b Investigators. Hirudin in acute myocardial infarction: thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9b Trial. Circulation 1996;94:911-21.
84. The GUSTO-IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
85. Wallentin L. Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes. Eur Heart J 1996;17:1470-6.
86. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost 1997;78:214-9.
87. Neuhaus K-L. More on thrombolysis and hemorrhagic stroke. Circulation 1995;92:2794-5.
88. Woo KS, White HD. Comparative tolerability profiles of thrombolytic agents. Drug Saf 1993;8:19-29.
89. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I Trial. Circulation 1995;92:2811-8.
90. Simoons ML, Maggioni AP, Knatterud G, Leimberger JD, de Jaegere P, van Domburg R, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342:1523-8.
91. Selker HP, Beshansky JR, Schmid CH, Griffith JL, Longstreth WT Jr, O'Connor CM, et al. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage: Thrombolytic Predictive Instrument (TPI) project results. Circulation 1994;90:1657-61.
92. Califf RM, Fortin DF, Tenaglia AN, Sane DC. Clinical risks of thrombolytic therapy. Am J Cardiol 1992;69(suppl):12A-20A.
93. Lew AS, Laramee P, Cercek B, Shah PK, Ganz W. The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation 1985;72:1321-6.
94. Verstraete M, Bory M, Collen D, Erbel R, Lennane RJ, Mathey D, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator. Lancet 1985;1:842-7.
95. Gemmill JD, Hogg KJ, Douglas JT, Dunn FG, Lowe GDO, Rae AP, et al. The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents - lack of relationship to pretreatment streptokinase resistance. Eur Heart J 1993;14:819-25.
96. Collen D. Thrombolytic therapy. Thromb Haemost 1997;78:742-6.
97. Verstraete M, Lijnen HR, Collen D. Thrombolytic agents in development. Drugs 1995;50:29-42.
98. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994;91:3670-4.
99. Benedict CR, Refmo CJ, Keyt BA, Pakala R, Paoni NF, Thomas R, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032-40.
100. Cannon CP, McCabe CH, Gibson M, Ghali M, Sequeira RF, McKendall GR, et al. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10a dose-ranging trial. Circulation 1997;95:351-6.
101. Smalling RW. A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes. Am J Health-Syst Pharm 1997;54(suppl 1):S17-S22.
102. Gurewich V. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. J Am Coll Cardiol 1987;10(suppl):16B-21B.
103. Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, et al. Thrombolytic properties of staphylokinase. Blood 1990;76:925-9.
104. Win W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning W-D. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs: fast and persistent recanalization by intravenous bolus administration. Circulation 1994;90:421-6.
105. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997;278:2093-8.
106. The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993;329:383-9.
107. Rawles J. Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT). BMJ 1996;312:212-6.
108. Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ, for the GUSTO Investigators. Holding GUSTO up to the light. Ann Intern Med 1994; 120:876-81.
109. Ridker PM, O'Donnell CJ, Marder VJ, Hennekens CH. A response to "holding GUSTO up to the light." Ann Intern Med 1994;120:882-5.
110. Ridker PM, Marder VJ, Hennekens CH. Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med 1993;119:530-2.
111. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-22.
112. Pfeffer MA, Moye LA, Braunwald E, Basta L, Brown EJ Jr, Cuddy TE, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991;266:528-32.
113. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-14.
114. Gurwitz JH, Gore JM, Goldberg RJ, Rubison M, Chandra N, Rogers WJ, et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996;124:283-91.
115. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med 1996;156:799-805.
116. Krumholz HM, Murillo JE, Chen J, Vaccarino V, Radford MJ, Ellerbeck EF, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA 1997;277:1683-8.